Comparing two BTK inhibitors for CLL/SLL after prior treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been diagnosed with CLL or SLL that has come back or stopped responding to treatment
- You have already been treated with a type of targeted therapy called a covalent BTK inhibitor (like ibrutinib, acalabrutinib, or zanubrutinib)
- You have not had a Richter's transformation or another type of lymphoma that needs treatment right now
- You are generally well enough to carry out everyday activities (ECOG score 0 to 2)
- You have not had a prior non-covalent BTK inhibitor or BTK degrader (a newer type of BTK drug)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a fixed-cycle treatment with a BTK inhibitor (a type of targeted therapy) to see which works better for CLL/SLL. It is for people who need treatment and have not had standard therapy before.
This study tests two drugs, pirtobrutinib and sonrotoclax, given together to treat certain types of B-cell lymphoma that have come back or not responded to other treatments. The combination may help shrink tumors or slow disease progression.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
This trial tests a new drug (BGB-16673) against another drug (pirtobrutinib) for people with CLL or SLL that hasn't responded to or has come back after a prior BTK inhibitor treatment. The goal is to see which drug is more effective and safe.
This study tests a new drug called NX-5948 against an existing drug (pirtobrutinib) for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to a previous BTK inhibitor treatment. The goal is to see if NX-5948 works better or is safer for this hard-to-treat situation.
Hear when a new CLL/SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.